Skip to contentP
Protagenic Therapeutics, Inc.\new
P
PTIXProtagenic Therapeutics, Inc.\new Q4 2021 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$0.00$0.00derived— vs Q4 2020 Net Income-$890.39K-$890.39KderivedN/M vs Q4 2020 EPS, diluted—Not derived. Share counts vary by quarter.
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Protagenic Therapeutics, Inc.\new · CIK 1022899 · Engraved from SEC EDGAR
Operating Incomederived-$861,219N/M Operating Cash Flowderived-$405,089N/M ended Dec 31, 2021 · filed Apr 7, 2022 · 97 d after period end